The role of chromogranin A as a biomarker in neuroendocrine tumours: Diagnostic and prognostic implications

#4398

Introduction: Chromogranin A (CgA) is a widely used serum biomarker for neuroendocrine tumours (NETs), reflecting tumour burden and secretory activity. Despite its clinical utility, the diagnostic sensitivity and prognostic value of CgA remain a subject of debate, especially given its potential for false positives and its variation across different NET subtypes.

Aim(s): To evaluate the diagnostic and prognostic significance of Chromogranin A in neuroendocrine tumours, and to assess its role in predicting treatment response and patient outcomes.

Materials and methods: A cohort of 150 patients diagnosed with NETs was retrospectively analysed. Serum CgA levels were measured at diagnosis and during follow-up. The relationship between CgA levels and tumour characteristics (e.g., size, location, Ki-67 index) was assessed. Furthermore, the role of CgA in predicting prognosis, including survival rates and response to therapy (e.g., somatostatin analogues and PRRT), was examined.

Conference:

Presenting Author:

Authors: Xu L, Ye M, Zeng X, Chen S, Ding Y,

Keywords: Chromogranin A, neuroendocrine tumour, diagnosis, prognosis, biomarker, Ki-67, metastatic disease,